Brendan Smith - 14 Sep 2021 Form 4 Insider Report for Translate Bio, Inc.

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 14 Sep 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 14 Sep 2021, 19:33:46 UTC
Next SEC filing: 15 Oct 2021
Source filing: View source filing
Reporting owner signature: /s/ Paul D. Burgess, as attorney-in-fact for Brendan Smith

Key filing fact

Brendan Smith filed Form 4 for Translate Bio, Inc. on 14 Sep 2021.

Key facts

This page summarizes Brendan Smith's Form 4 filing for Translate Bio, Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 14 Sep 2021, 19:33.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TBIO transaction Derivative

Stcok Option (right to buy)

Sale

Transaction value: $0
Shares: -201,800
Change %: -100%
Price: $0.000000^*
Shares after: 0
Date: 14 Sep 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 201,800
Exercise price: $19.23
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

As of September 14, 2021, Issuer was acquired in a cash tender by an indirect subsidiary of Sanofi, a French societe anonyme at a purchase price of $38.00 per share (the "Tender Offer"), as described more fully in the Schedule 14D-9 filed by the Issuer on August 16, 2021. Under the terms of the Tender Offer, Issuer outstanding stock options, if not vested became vested, and all Issuer stock options were converted into cash consideration at the amount of the difference between the exercise price of the option and the Tender Offer price of $38.00 per share.

Footnote F2

This option was granted on April 19, 2021. The shares underlying this option are scheduled to vest over four years, with 25% of the shares vesting on April 19, 2022 and the remainder vesting in equal monthly installments through April 19, 2025.